Literature DB >> 2454947

Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models.

F Gigliotti1, W T Hughes.   

Abstract

Pneumocystis carinii is an important cause of pneumonitis in the immunosuppressed host. Little is known, however, about the biology of this organism. This report demonstrates that a MAb, M5E12, previously shown to be directed against a surface antigen that is present on rat-, rabbit-, ferret-, and human-derived P. carinii, is capable of hindering the development of P. carinii pneumonitis in animal models of this infection when administered throughout the period of immunosuppression. It appears that MAb M5E12 thus has identified a surface antigen of P. carinii that is important in host-parasite interactions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454947      PMCID: PMC442608          DOI: 10.1172/JCI113503

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  12 in total

1.  Failure of monoclonal antibodies to core glycolipid to bind intact smooth strains of Escherichia coli.

Authors:  F Gigliotti; J L Shenep
Journal:  J Infect Dis       Date:  1985-06       Impact factor: 5.226

2.  Pneumocystis carinii infection.

Authors:  B A Burke; R A Good
Journal:  Medicine (Baltimore)       Date:  1973-01       Impact factor: 1.889

3.  Development of murine monoclonal antibodies to Pneumocystis carinii.

Authors:  F Gigliotti; D C Stokes; A B Cheatham; D S Davis; W T Hughes
Journal:  J Infect Dis       Date:  1986-08       Impact factor: 5.226

4.  Protection from infection with Haemophilus influenzae type b by monoclonal antibody to the capsule.

Authors:  F Gigliotti; R A Insel
Journal:  J Infect Dis       Date:  1982-08       Impact factor: 5.226

5.  Production of monoclonal antibody against Pneumocystis carinii by using a hybrid of rat spleen and mouse myeloma cells.

Authors:  C H Lee; C D Bolinger; M S Bartlett; R B Kohler; C E Wilde; J W Smith
Journal:  J Clin Microbiol       Date:  1986-03       Impact factor: 5.948

6.  Development and characterization of monoclonal antibodies to Pneumocystis carinii.

Authors:  D C Graves; S J McNabb; M H Ivey; M A Worley
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

7.  Experimental Pneumocystis carinii pneumonia in the ferret.

Authors:  D C Stokes; F Gigliotti; J E Rehg; R L Snellgrove; W T Hughes
Journal:  Br J Exp Pathol       Date:  1987-04

8.  Experimental Pneumocystis carinii infection in nude rats.

Authors:  T Furuta; K Ueda; K Fujiwara
Journal:  Jpn J Exp Med       Date:  1984-04

9.  Effect of T-cell transfer on Pneumocystis carinii infection in nude mice.

Authors:  T Furuta; K Ueda; S Kyuwa; K Fujiwara
Journal:  Jpn J Exp Med       Date:  1984-04

10.  Humoral immunity in experimental Pneumocystis carinii infection. I. Serum and bronchial lavage fluid antibody responses in rats.

Authors:  P D Walzer; M E Rutledge
Journal:  J Lab Clin Med       Date:  1981-06
View more
  51 in total

Review 1.  Immunological features of Pneumocystis carinii infection in humans.

Authors:  P D Walzer
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

2.  Seroepidemiological study of Pneumocystis jirovecii infection in healthy infants in Chile using recombinant fragments of the P. jirovecii major surface glycoprotein.

Authors:  Kpandja Djawe; Kieran R Daly; Sergio L Vargas; M Elena Santolaya; Carolina A Ponce; Rebeca Bustamante; Judith Koch; Linda Levin; Peter D Walzer
Journal:  Int J Infect Dis       Date:  2010-12       Impact factor: 3.623

3.  Complement and Fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia.

Authors:  Jesse Wells; Constantine G Haidaris; Terry W Wright; Francis Gigliotti
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

4.  Trimethoprim-sulfamethoxazole treatment does not reverse obstructive pulmonary changes in pneumocystis-colonized nonhuman primates with SHIV infection.

Authors:  Heather M Kling; Timothy W Shipley; Siobhan Guyach; Rebecca Tarantelli; Alison Morris; Karen A Norris
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

Review 5.  Antibody immunity and invasive fungal infections.

Authors:  A Casadevall
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

Review 6.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Characterization of major surface glycoprotein genes of human Pneumocystis carinii and high-level expression of a conserved region.

Authors:  Q Mei; R E Turner; V Sorial; D Klivington; C W Angus; J A Kovacs
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  Characterization of multiple unique cDNAs encoding the major surface glycoprotein of rat-derived Pneumocystis carinii.

Authors:  M J Linke; A G Smulian; J R Stringer; P D Walzer
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

9.  Proliferative and cytokine responses to a major surface glycoprotein of Pneumocystis carinii.

Authors:  S A Theus; M J Linke; R P Andrews; P D Walzer
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

10.  Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD8+ T cells into severe combined immunodeficiency mice.

Authors:  J B Roths; C L Sidman
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.